Pure Global: EU's MedTech Shortage & The New Supply Rules

The European Union is taking decisive action to combat the critical shortage of medical devices, a problem that has plagued its healthcare systems since the rollout of MDR. This episode unpacks the European Commission's new proposal for a mandatory six-month notification period for discontinuing devices, and what it means for manufacturers. This isn't just another form to fill out. it's a fundamental shift in market responsibility that directly impacts product lifecycle management, supply chain forecasting, and your competitive position. We explore the strategic challenges and opportunities this new era of mandatory transparency creates for MedTech companies operating in the EU. A French manufacturer of a critical diagnostic assay decides to discontinue the product due to low margins and high MDR compliance costs. Their plan was to quietly phase it out within three months. Suddenly, they are faced with the new six-month mandatory notification rule, forcing them to continue production at a loss, manage difficult conversations with distributors, and alert competitors to their exit strategy far earlier than intended, creating a significant strategic dilemma. Key Takeaways: - What triggers the mandatory six-month shortage notification requirement in the EU? - How does this new rule change the financial calculation for discontinuing a legacy product? - What specific information must manufacturers now provide to competent authorities? - How can you turn supply chain transparency into a competitive advantage in the EU market? - What are the legal and commercial risks of failing to comply with this new proposal? - How should this rule affect your product portfolio and end-of-life strategies? - Does this new EU rule align with or diverge from supply notification rules in the US or other markets? Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.